Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1044 | 888 | 1103 | 972 | 1322 | - |
Fund Return | 4.37% | -11.17% | 10.27% | -0.94% | 5.73% | - |
Place in category | 649 | 908 | 618 | 422 | 214 | - |
% in Category | 62 | 91 | 61 | 63 | 45 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cleome Index USA Equities I USD Acu | 3.08B | 27.47 | 10.18 | - | ||
Cleome Index USA Eq C USD Inc | 3.08B | 19.36 | 6.70 | - | ||
Cleome Index USA Eq C USD Acc | 3.08B | 19.36 | 6.70 | 11.13 | ||
Cleome Index USA Equities Z USD Acc | 3.08B | 20.26 | 7.75 | 12.32 | ||
LU1864481541 | 1.58B | 4.37 | -0.94 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
World Healthscience Fund C2u | 367.4M | 6.72 | 2.28 | 6.20 | ||
World Healthscience Fund D2u | 1.21B | 8.68 | 4.34 | 8.34 | ||
World Healthscience Fund X2 USD | 43.76M | 9.68 | 5.37 | 9.43 | ||
World Healthscience Fund A2 | 6.39B | 7.93 | 3.57 | 7.53 | ||
World Healthscience Fund E2 | 2.09B | 7.45 | 3.05 | 6.99 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 5.50 | 779.06 | +1.47% | |
AstraZeneca | GB0009895292 | 4.95 | 10,452.0 | +1.91% | |
Merck&Co | US58933Y1055 | 4.78 | 98.72 | +0.69% | |
Amgen | US0311621009 | 4.78 | 263.41 | +0.01% | |
Roche Holding Participation | CH0012032048 | 4.57 | 250.70 | +1.33% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review